CAMP4 THERAPEUTICS CORPORATION (CAMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) has a cash flow conversion efficiency ratio of -0.355x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.98 Million) by net assets ($30.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CAMP net asset quality score to measure how much of total assets are equity-financed.
CAMP4 THERAPEUTICS CORPORATION - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CAMP cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CAMP4 THERAPEUTICS CORPORATION Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CAMP4 THERAPEUTICS CORPORATION ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Afrimat
JSE:AFT
|
0.117x |
|
Computer Modelling Group Ltd.
TO:CMG
|
0.000x |
|
Kolon Corp
KO:002020
|
-0.014x |
|
American Resources Corp Class A
NASDAQ:AREC
|
-0.127x |
|
Evans Bancorp Inc
NYSE MKT:EVBN
|
-0.022x |
|
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
|
-0.005x |
|
Coca Cola HBC AG
LSE:CCH
|
0.256x |
|
Somany Ceramics Limited
NSE:SOMANYCERA
|
0.119x |
Annual Cash Flow Conversion Efficiency for CAMP4 THERAPEUTICS CORPORATION (1989–2025)
The table below shows the annual cash flow conversion efficiency of CAMP4 THERAPEUTICS CORPORATION from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see CAMP market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $47.70 Million | $-29.55 Million | -0.620x | +14.14% |
| 2024-12-31 | $63.14 Million | $-45.56 Million | -0.722x | -302.19% |
| 2023-12-31 | $-123.73 Million | $-44.16 Million | 0.357x | -28.21% |
| 2022-12-31 | $-77.53 Million | $-38.54 Million | 0.497x | +1045.01% |
| 2021-12-31 | $80.18 Million | $-4.22 Million | -0.053x | -118.28% |
| 2020-12-31 | $99.32 Million | $28.59 Million | 0.288x | +243.86% |
| 2019-12-31 | $137.92 Million | $11.54 Million | 0.084x | -63.94% |
| 2018-12-31 | $205.65 Million | $47.74 Million | 0.232x | -30.97% |
| 2017-12-31 | $198.92 Million | $66.89 Million | 0.336x | +113.79% |
| 2016-12-31 | $164.00 Million | $25.80 Million | 0.157x | -37.13% |
| 2015-12-31 | $189.45 Million | $47.40 Million | 0.250x | +32.23% |
| 2014-12-31 | $151.38 Million | $28.64 Million | 0.189x | +10.42% |
| 2013-12-31 | $133.15 Million | $22.82 Million | 0.171x | +21.37% |
| 2012-12-31 | $117.55 Million | $16.60 Million | 0.141x | -71.63% |
| 2011-12-31 | $24.98 Million | $12.43 Million | 0.498x | +922.31% |
| 2010-12-31 | $17.60 Million | $857.00K | 0.049x | -62.19% |
| 2009-12-31 | $19.20 Million | $2.47 Million | 0.129x | -78.29% |
| 2008-12-31 | $23.20 Million | $13.76 Million | 0.593x | +3050.37% |
| 2007-12-31 | $73.42 Million | $-1.48 Million | -0.020x | -118.18% |
| 2006-12-31 | $151.25 Million | $16.72 Million | 0.111x | -13.00% |
| 2005-12-31 | $176.11 Million | $22.38 Million | 0.127x | +60.46% |
| 2004-12-31 | $158.29 Million | $12.54 Million | 0.079x | +1.62% |
| 2003-12-31 | $65.36 Million | $5.09 Million | 0.078x | -16.61% |
| 2002-12-31 | $58.62 Million | $5.48 Million | 0.093x | -71.47% |
| 2001-12-31 | $37.58 Million | $12.31 Million | 0.328x | +32.12% |
| 2000-12-31 | $30.28 Million | $7.51 Million | 0.248x | +2277.78% |
| 1999-12-31 | $28.09 Million | $293.00K | 0.010x | -96.49% |
| 1998-12-31 | $20.20 Million | $6.00 Million | 0.297x | +114.85% |
| 1997-12-31 | $21.70 Million | $3.00 Million | 0.138x | +162.86% |
| 1996-12-31 | $24.10 Million | $-5.30 Million | -0.220x | -148.89% |
| 1995-12-31 | $22.90 Million | $10.30 Million | 0.450x | +97.11% |
| 1994-12-31 | $14.90 Million | $3.40 Million | 0.228x | +1027.96% |
| 1993-12-31 | $12.20 Million | $-300.00K | -0.025x | -107.80% |
| 1992-12-31 | $7.30 Million | $2.30 Million | 0.315x | -22.28% |
| 1991-12-31 | $3.70 Million | $1.50 Million | 0.405x | +170.27% |
| 1990-12-31 | $2.00 Million | $300.00K | 0.150x | +50.00% |
| 1989-12-31 | $2.00 Million | $200.00K | 0.100x | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more